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Background: Liraglutide is an analog of human glucagon-like peptide-1 (GLP-1) and acts 
as a GLP-1 receptor agonist. Liraglutide is presently used in the treatment of selected patients 
with type 2 diabetes mellitus (T2DM).
Objective: To assess efficacy and safety of liraglutide in, overweight and obese Indian patients 
with T2DM.
Methods: A single center, prospective, open-labeled, single-arm, observational study for 
24 weeks in a real-world setting. Fourteen overweight and obese patients with T2DM who were 
clinically suitable for liraglutide therapy received liraglutide injections. The starting dose of 
liraglutide (Victoza) injection was 0.6 mg/day for 3 days followed by 1.2 mg for next 10 days and 
finally 1.8 mg/day for 22 weeks. Patients were evaluated at baseline and after 12 and 24 weeks of 
therapy. Adverse events (AE) noted during course of therapy were recorded. A repeated measure 
analysis of variance was performed to assess statistical significance.
Results: Fourteen patients were studied for 24 weeks. After 24 weeks of liraglutide therapy, mean 
fasting and postprandial plasma glucose decreased by 48.5 mg/dL and 66.71 mg/dL, respectively 
(P = 0.002 and P = 0004 over 24 weeks, respectively). A mean reduction of 2.26% of glycosylated 
hemoglobin was noted (P , 0.001 over 24 weeks). Mean decrease in body weight of 8.65 kg and 
mean decrease in body mass index of 3.26 kg/m2 was noted (P , 0.001 over 24 weeks for each 
parameter). Systolic blood pressure was reduced by 15.15 mm of Hg (P = 0.004). Significant 
improvement in total cholesterol, low-density lipoprotein,   triglycerides, and serum creatinine 
was noted. Nine patients reported AEs. The AEs noticed were nausea (n = 6), feeling of satiety 
(n = 3), and vomiting (n = 1). No serious AE or hypoglycemic   episodes were observed.
Conclusion: Liraglutide once a day improved overall glycemic control and was well tolerated. 
Clinically significant reduction in body weight, systolic blood pressure and improvement in 
lipid profile were noticed with liraglutide therapy in addition to glycemic control.
Keywords: liraglutide, weight loss, type 2 diabetes, obesity, GLP-1 analog, lipid profile, blood 
pressure, India
Introduction
A good majority of patients with type 2 diabetes (T2DM) present with concomitant 
obesity. The increase in prevalence of obesity over the last 20 years closely parallels the 
increase in prevalence of T2DM.1 Cultural changes in terms of food preferences and 
easy availability of convenience foods, irregular meals, frequent snacking on energy-
dense fast foods, consumption of animal foods, sweetened carbonated drinks, low 
intake of fiber, monounsaturated fatty acids (MUFAs), and n-3 polyunsaturated fatty 
acids (PUFAs) are leading to an increased prevalence of obesity in India.2 The recently 
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published Indian Council of Medical Research – India DIA-
Betes (ICMR–INDIAB) study projected a prevalence rate of 
62.4 million and 77.2 million people in India with diabetes 
and prediabetes, respectively. This study also highlighted 
the association of abdominal obesity as a predominant risk 
factor for   prediabetes and T2DM.3
Weight reduction is the corner stone in the management of 
T2DM, and is reported to increase insulin sensitivity, reduce 
blood pressure, improve lipid profile, and reduces markers of 
inflammation, coagulation, and endothelial dysfunction.4 As 
T2DM is a complex, multifactorial, and progressive disorder, 
maintaining an individualized glycemic target is always chal-
lenging for both patient and the treating physician. Therefore 
there is a need for newer drugs in the effective management 
of T2DM. Incretin-based therapies for treatment of T2DM 
are a recent addition in the therapeutic armamentarium of 
diabetes management.
Liraglutide (Victoza; Novo Nordisk A/S, Bagsværd, 
Denmark) is an analog of human glucagon-like peptide-1 
(GLP-1) and acts as a GLP-1 receptor agonist. It is indicated 
as an adjunct to diet and exercise to improve glycemic control 
in adults with T2DM.5 Liraglutide is available in India since 
July 2010. We present an observational study of liraglutide in 
newly diagnosed overweight and obese Indian patients with 
T2DM from a diabetes research center in India.
Materials and methods
This was a single center, prospective, open-labeled, single-
arm, observational study of 24 weeks duration in a real-world 
setting. T2DM patients with coexisting overweight and obesity 
clinically suitable for liraglutide therapy were enrolled and 
managed with Diabetes Tele Management System (DTMS®)6 
at Jothydev’s Diabetes Research Center at Trivandrum, Kerala, 
India. DTMS® is a unique telemedicine tool in vogue since 
1998. It consists of special software, networked computers, 
and a multidisciplinary team that follows up diabetes 
patients via telephone or Internet and provides continuous 
education, modification of dosages and lifestyles, and ensures 
compliance with therapeutic instructions. The team comprises 
of more than 20 trained doctors, educators, dietitians, nurses, 
pharmacists, and a psychologist.
Patients with known contraindications for liraglutide 
therapy (based on prescribing information of Victoza® injec-
tion) were excluded from the study. This study complied with 
the principles of the Declaration of Helsinki. Formal written 
informed consent for participation in the study was obtained 
from each patient.
Individualized diet modification and exercise plan was 
discussed and prescribed for all patients. All patients received 
liraglutide therapy in addition to their existing antidiabetic 
therapy. The starting dose of liraglutide (Victoza) injection 
was 0.6 mg/day for 3 days which was escalated to 1.2 mg 
for next 10 days and finally 1.8 mg/day for 22 weeks. There 
was no washout period for the drugs previously used in 
these patients and the duration of therapy was 24 weeks 
(6 months).
All patients were evaluated at baseline, after 12 weeks and 
after 24 weeks of therapy. Physical examination, glycemic 
control (fasting and postprandial plasma glucose [FPG; PPG], 
glycosylated hemoglobin [HbA1c]), lipid profile and other 
relevant investigations as required were repeated.
The doses of other antidiabetic drugs were   modified 
as and when required via DTMS®. After 24 weeks of 
therapy, liraglutide was tapered and stopped and patients 
were   continued on minimal/no drugs and lifestyle 
modifications.
The safety and tolerability of liraglutide was assessed 
continuously during the study and any adverse event (AE) 
noted during course of therapy was recorded. Additionally 
kidney function was evaluated at every visit.
Statistical methods
Descriptive statistical analysis has been carried out in 
the present study. Results on continuous measurements 
are presented on mean ± standard deviation (min–max) 
and results on categorical measurements are presented 
in percentages. Statistical significance was assessed 
at a 5% level. The following assumptions on data 
were made, Assumptions: (i) dependent variables were 
normally distributed, (ii) samples drawn from the population 
were random and samples of the cases were independent. 
Table 1 Baseline demographic data
Sr no Parameter Observed value
1. number of patients 14
2. Male:female 7:7
3. Age (years, mean ± SD) 43.64 ± 13.89
4. Duration of T2DM (weeks, mean ± SD) 33.50 ± 80.28
5. height (cm, mean ± SD) 165.36 ± 14.57
6. Weight (kg, mean ± SD) 90.71 ± 11.80
7. Body mass index (kg/m2, mean ± SD) 33.49 ± 5.15
8. Systolic blood pressure  
(mmhg, mean ± SD)
137.86 ± 13.89
9. Diastolic blood pressure  
(mmhg, mean ± SD)
78.29 ± 8.77
Abbreviation: SD, standard deviation.
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Repeated measures analysis of variance has been performed 
to find the significance of change of study variables over 
baseline, after 12 weeks, and after 24 weeks. The difference 
was considered as significant with P values of ,0.1 to 0.05, 
moderately significant with P values of ,0.05 to 0.01 and 
strongly significant with P value of ,0.01.7–10
Statistical software
The statistical software, SAS (version 9.2; SAS Institute, 
Cary, NC) and R environment (version 2.11.1; R Foundation 
for Statistical Computing, Vienna, Austria), were used for 
the analysis of the data.
Results
Fourteen patients (seven male and seven female) receiving 
liraglutide therapy were followed-up for 24 weeks. Baseline 
demographic data is shown in Table 1. Mean (SD) age of 
43.64 (13.89) years and majority (12/14) of patients had 
T2DM of less than 12 weeks duration. The mean weight and 
body mass index (BMI) were 90.71 (11.80) kg and 33.49 
(5.15) kg/m2, respectively.
With 12 weeks of liraglutide therapy, mean decrease in FPG 
and PBG was 45.21 mg/dL and 50.07 mg/dL, respectively. 
After 24 weeks of therapy, FPG and PPG decreased by 
48.5 mg/dL and 66.71 mg/dL, respectively (Table 2 and 
  Figure 1). A quadratic change in reduction of FPG and 
PPG was noted over 24 weeks (P = 0.002 and 0.004, 
respectively).
Similarly HbA1c decreased by 1.36% and 2.26% after 
12 and 24 weeks of therapy, respectively. A linear reduc-
tion in HbA1c over 12 and 24 weeks was noted (P , 0.001) 
(Table 2 and Figure 2).
Significant reduction in body weight and BMI were 
noted over 24 weeks (-8.65 kg, P , 0.001 and -3.26 kg/m2, 
P , 0.001) (Table 3 and Figure 3).
A significant decrease in systolic blood pressure (SBP) of 
15.15 mm of Hg (P = 0.004) and decrease in diastolic blood 
pressure (DBP) of 1.29 mm of Hg was noted over 24 weeks 
of therapy (Table 4).
Prior to starting liraglutide therapy, subjects were on 
  various therapeutic regimens. With start of liraglutide 
therapy, concomitant drugs were modified. After 12 and 
24 weeks of liraglutide therapy, the requirement of other 
antidiabetic drugs were modified via DTMS® as and when 
required (Table 5). Significant improvement was noted in 
total cholesterol, high-density lipoprotein, and triglycerides 
over 24 weeks of therapy (Table 6). Significant reduction in 
serum creatinine was also noted (Table 6).
Nine patients reported AEs. The most common AE 
was nausea (n = 6) followed by feeling of satiety (n = 3), 
Table 2 Improvement in glycemic control
Baseline After 12 weeks After 24 weeks P value (Change)
FBG (mg/dL) 147.57 ± 46.68 102.36 ± 29.90   99.07 ± 22.55 0.002**  
(Quadratic change)
PPBG (mg/dL) 167.57 ± 77.44 117.50 ± 40.79 100.86 ± 35.72 0.004**  
(Quadratic change)
hbA1c (%)     7.78 ± 1.74     6.42 ± 1.10     5.52 ± 0.53 ,0.001**  
(Linear change)
Notes: Results are presented in mean ± SD, P values are repeated measures analyses of variance; **strongly significant.
Abbreviations: FBG, fasting blood glucose; PPBG, postprandial blood glucose; hbA1c, glycosylated hemoglobin.
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Figure 1 Reduction in fasting and post-prandial blood glucose.
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Figure 2 Reduction in hbA1c.
Table 3 Decrease in weight and body mass index
Weight  
(kg)
Body mass index 
(kg/m2)
Baseline 90.71 ± 11.80 33.49 ± 5.15
After 12 weeks of therapy 85.69 ± 12.20 31.61 ± 5.00
After 24 weeks of therapy 82.06 ± 12.86 30.23 ± 5.01
P value ,0.001** ,0.001**
Notes:  Results  are  presented  in  mean  ±  SD,  P  values  are  repeated  measures 
analyses of variance; **strongly significant.
and vomiting (n = 1). Nausea persisted for 1–2 weeks in 
five of six patients, while in one patient it subsided after 
5 days of therapy. Vomiting was seen in one subject for 
the first 3 days, while feeling of satiety was noticed for 
1 month in three patients. All AEs were of minimal clinical 
significance and self-limiting. None of the patients reported 
any   serious AE.
Discussion
Currently conventional diabetes management does not 
address the diminution of the incretin effect, recognized as 
one of the key pathophysiological defects in T2DM. Since 
insulin resistance and obesity are key pathophysiological 
factors resulting in the development of T2DM, therapies 
addressing these may be of potential importance. Presently, 
except metformin, treatment with sulphonylureas, thiazo-
lidinediones, and insulin eventually result in weight gain 
during the course of therapy. GLP-1 analogs are a new group 
of therapeutic agents which help attain normoglycemia along 
with weight loss.
Liraglutide (Victoza; Novo Nordisk A/S) is a   modified 
form of human GLP-1 analog acting as a GLP-1   receptor 
agonist and is available in India for more than a year. 
Many studies evaluated and established the efficacy and 
safety of liraglutide in T2DM. These studies reported 
that liraglutide decreases HbA1c in monotherapy and in 
  combination with other antidiabetic drugs; inhibits   glucagon 
secretion, decreases gastric emptying, and also results in 
weight loss.11
We evaluated the efficacy and safety of liraglutide in 
overweight and obese Indian T2DM patients. A majority 
of the patients (85.71% (12/14)) had been diagnosed with 
diabetes less than 12 weeks prior to starting liraglutide 
therapy. A single-center study, small sample size, open 
label, and noncomparative design are the limitations of the 
present study and therefore our results must be interpreted 
with caution. Additionally we could not assess insulin 
resistance and beta cell function due to nonavailability of 
equipment and resources. Nevertheless, the results represent 
data from a real-life clinical setting and appears clinically 
significant with some interesting findings of the effect of 
liraglutide therapy in management of overweight and obese 
T2DM patients.
This limited group of patients reported slightly more 
decrease in HbA1c (2.26% at 24 weeks) compared to other 
published LEAD studies.12–17
The effects of liraglutide on body weight appear quite 
interesting in this study. After, 12 weeks of liraglutide 
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Figure 3 Reduction in weight and body mass index.
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1.8 mg/day therapy, mean reduction in body weight was 
5.02 kg and after 24 weeks of therapy, total reduction in 
body weight was 8.65 kg (P , 0.001). Similarly, BMI 
was decreased by 3.26 kg/m2 after 24 weeks of therapy 
(P , 0.001). Published evidence from LEAD studies have 
reported an average decrease of 3.39 kg weight at 52 weeks 
of therapy and 3.24 kg in 26 weeks.14,17
Jendle et al reported that there is reduction in fat mass 
rather than tissue mass with liraglutide therapy. Additionally, 
it was noted that there was more reduction in visceral fat 
than subcutaneous abdominal fat.18 The weight loss could be 
as a result of the delayed gastric emptying and early satiety 
induced by liraglutide. Reduction of weight is a cornerstone 
in management of T2DM as it is associated with improve-
ment in insulin sensitivity, reduction in blood pressure, and 
improvement in lipid profile. Therefore a mean reduction of 
8.65 kg body weight over 24 weeks could have significant 
clinical effects in the management of T2DM.
This study also highlights the place of liraglutide in 
  prediabetes and newly diagnosed patients with T2DM, 
as the majority of patients (85.71%) were having diabetes 
duration of ,12 weeks. In the present study, glycemic con-
trol close to normal levels (mean FPG, PPG, and HbA1c of 
99.07 mg/dL, 100.86 mg/dL, and 5.52%, respectively) was 
achieved within 24 weeks of liraglutide therapy. This may be 
due to the significant reduction in weight along with other 
effects of liraglutide. This study also points to a possibility of 
  completely reversing T2DM leading to no therapy or minimal 
therapy after an initial course of liraglutide for 24 weeks. 
In this study after 24 weeks of therapy liraglutide was tapered 
and stopped after achieving euglycemia and patients were 
continued on lifestyle modifications and minimal drugs. 
These patients are currently being followed up and assessed 
to check on the long term outcomes and this data would be 
published at a later stage.
Another interesting finding was the significant reduction 
in SBP. Over 24 weeks of liraglutide 1.8 mg/day therapy, SBP 
was reduced by 15.15 mm of Hg (P = 0.004). Additionally 
there was positive improvement in lipid profile in terms of 
significant reduction in total cholesterol (P , 0.001), low-
density lipoproteins (P = 0.001) and serum triglycerides 
(P = 0.002) over 24 weeks. As these are independent risk 
factors for cardiovascular (CV) disease, reduction in BP and 
improvement in lipid profile reported by liraglutide therapy 
may be associated with improved CV outcome in T2DM. 
Reported evidence suggests that liraglutide must not be 
administered in moderate to severe renal failure and there 
have been postmarketing reports of acute renal failure and 
worsening of chronic renal failure, which may sometimes 
require hemodialysis in liraglutide-treated patients. However 
significant reduction in serum creatinine was noted in this 
study (P = 0.027).
We also observed that addition of liraglutide injection 
reduced the requirement of other antidiabetic drugs.
Table 4 Improvement in blood pressure
Systolic  
blood pressure  
(mmHg)
Diastolic  
blood pressure   
(mmHg)
Baseline 137.86 ± 13.89 78.29 ± 8.77
After 12 weeks of therapy 127.71 ± 13.81 76.21 ± 9.24
After 24 weeks of therapy 122.71 ± 10.38 77.00 ± 10.41
P value 0.004** 0.767
Notes:  Results  are  presented  in  mean  ±  SD,  P  values  are  repeated  measures 
analyses of variance; **strongly significant.
Table 5 Antidiabetic and other drugs coprescribed
Prior to  
study
Baseline After  
12 weeks
After  
24 weeks
Metformin, (n) 07 13 11 09
Sulfonylurea, (n) 02 01 00 00
DPP-4 I, (n) 02 00 00 00
Statin, (n) 05 09 06 04
ARB, (n) 02 03 03 02
Beta-blocker, (n) 02 02 02 02
Notes: Total patients: 14; patient may be taking more than 1 drug; n: number of 
patients.
Abbreviations:  DPP-4  I,  Dipeptidyl  peptidase  4  inhibitor;    ARB,  angiotensin 
receptor blocker.
Table 6 Improvement in lipid profile and kidney function test
Baseline After 12 weeks After 24 weeks P value
Total cholesterol, (mg/dL) 166.07 ± 38.53   134.5 ± 25.35 125.14 ± 22.04 ,0.001**
hDL, (mg/dL)   43.14 ± 11.98   42.21 ± 9.82   41.21 ± 9.48 0.236
LDL, (mg/dL)   94.21 ± 30.92   74.71 ± 25.26     64.5 ± 21.17 0.001**
TG, (mg/dL) 129.07 ± 56.34 103.64 ± 43.37   93.36 ± 36.68 0.002**
Serum creatinine, (mg/dL)     0.81 ± 0.12     0.78 ± 0.07     0.75 ± 0.05 0.027*
Urine albumin, (mg/dL)   15.64 ± 14.57   10.05 ± 4.05     8.71 ± 0.91 0.108
Notes: Results are presented in mean ± SD, P values are repeated measures analyses of variance; *moderately significant; **strongly significant.
Abbreviations: hDL, high-density lipoprotein; LDL, low-density lipoprotein; TG, triglycerides.
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Liraglutide was well tolerated in these Indian patients. 
There was no episode of hypoglycemia or any other serious 
AE. All observed AEs were of minor clinical significance 
and as reported in published literature.
Conclusion
In this 24-week, prospective, open-labeled, single-center 
study, liraglutide once a day in combination with metformin 
over a period of 6 months significantly improved glycemic 
control to normal level and was well tolerated in the   majority 
of patients. Additionally clinically significant reduction in 
body weight, systolic blood pressure and improvement in 
lipid profile were noticed with liraglutide. However these 
results need to be interpreted with caution and need to be 
replicated in large multicentric randomized controlled trials 
for establishing the effects of liraglutide beyond glycemic 
control. The observation that liraglutide therapy results in 
probable remission of newly diagnosed T2DM needs to be 
established in randomized controlled trials.
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